ap611074
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2012 (NCT01532102)
Timeline
Indications
Mechanism of action
- Human papillomavirusINHIBITOR
Human papillomavirus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ap611074
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02724254 | Phase 2 | Jan 1, 2016 | Anaconda Pharma, Aviragen Therapeutics |
| NCT01532102 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2012 | Anaconda Pharma, University of Paris |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anaconda Pharma | For profit | 2 | 2 | 1 | 2012 |
| Aviragen Therapeutics | For profit | 1 | 0 | 1 | 2016 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2012 |
3 organizations
Page 1 / 1